CN108473973A - 包含负载蛋白的外泌体的组合物以及制备和递送该组合物的方法 - Google Patents

包含负载蛋白的外泌体的组合物以及制备和递送该组合物的方法 Download PDF

Info

Publication number
CN108473973A
CN108473973A CN201780003826.5A CN201780003826A CN108473973A CN 108473973 A CN108473973 A CN 108473973A CN 201780003826 A CN201780003826 A CN 201780003826A CN 108473973 A CN108473973 A CN 108473973A
Authority
CN
China
Prior art keywords
excretion body
leu
ala
gly
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780003826.5A
Other languages
English (en)
Chinese (zh)
Inventor
崔哲熙
崔暻善
柳承旭
任男彬
崔皓竣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elias Biological Products Co ltd
Original Assignee
Life Science Cos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020160126961A external-priority patent/KR101912315B1/ko
Priority claimed from KR1020160126335A external-priority patent/KR101877010B1/ko
Priority claimed from KR1020160126921A external-priority patent/KR101912313B1/ko
Priority claimed from KR1020160127486A external-priority patent/KR101912310B1/ko
Priority claimed from KR1020160132616A external-priority patent/KR101900465B1/ko
Application filed by Life Science Cos filed Critical Life Science Cos
Publication of CN108473973A publication Critical patent/CN108473973A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01015—Peroxiredoxin (1.11.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
CN201780003826.5A 2016-09-30 2017-09-29 包含负载蛋白的外泌体的组合物以及制备和递送该组合物的方法 Pending CN108473973A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
KR10-2016-0126335 2016-09-30
KR1020160126961A KR101912315B1 (ko) 2016-09-30 2016-09-30 Bax 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
KR1020160126335A KR101877010B1 (ko) 2016-09-30 2016-09-30 super-repressor-IκB 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약학적 조성물
KR1020160126921A KR101912313B1 (ko) 2016-09-30 2016-09-30 Cre 재조합 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 표적 유전자의 조건적 녹아웃 대립유전자를 생성하기 위한 조성물
KR10-2016-0126961 2016-09-30
KR10-2016-0126921 2016-09-30
KR10-2016-0127486 2016-10-04
KR1020160127486A KR101912310B1 (ko) 2016-10-04 2016-10-04 페록시레독신 i 또는 ii 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 항산화용 약학적 조성물
KR10-2016-0132616 2016-10-13
KR1020160132616A KR101900465B1 (ko) 2016-10-13 2016-10-13 CRISPR-CAS family를 이용한 게놈 에디팅 툴을 엑소솜으로 전달하는 기술
KR10-2017-0018637 2017-02-10
KR20170018637 2017-02-10
PCT/KR2017/011070 WO2018062973A1 (fr) 2016-09-30 2017-09-29 Compositions contenant un exosome chargé d'une protéine, et procédés de préparation et d'administration correspondants

Publications (1)

Publication Number Publication Date
CN108473973A true CN108473973A (zh) 2018-08-31

Family

ID=61760013

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780003826.5A Pending CN108473973A (zh) 2016-09-30 2017-09-29 包含负载蛋白的外泌体的组合物以及制备和递送该组合物的方法

Country Status (7)

Country Link
EP (1) EP3356522A4 (fr)
JP (1) JP2019528674A (fr)
CN (1) CN108473973A (fr)
AU (1) AU2017335084B2 (fr)
CA (1) CA3002520A1 (fr)
IL (1) IL259023B (fr)
WO (1) WO2018062973A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109097336A (zh) * 2018-09-07 2018-12-28 深圳市新仑生物科技有限公司 一种干细胞外泌体、制备方法及应用
CN110387416A (zh) * 2018-04-16 2019-10-29 华东理工大学 可控聚合调控功能的纳米金双探针体系及其应用
CN110669723A (zh) * 2019-11-08 2020-01-10 赵凯 一种基于差速离心法的细胞外泌体提取工艺
CN110885789A (zh) * 2018-09-05 2020-03-17 中国科学院生物物理研究所 高效可控包装內源核酸的工程化外泌体制备及其应用
CN111905105A (zh) * 2020-07-02 2020-11-10 华南师范大学 一种用于癌症靶向治疗的蛋白类纳米药物及其制备方法
CN113388584A (zh) * 2020-03-10 2021-09-14 路宝特（南京）环保科技有限公司 一种促进皮肤组织损伤后修复用工程化外泌体的制备方法及其应用
CN113447658A (zh) * 2021-07-01 2021-09-28 浙江大学医学院附属儿童医院 一种检测抗过氧化物还原酶-1-IgG抗体的试剂盒
CN114901259A (zh) * 2019-12-30 2022-08-12 伊利亚斯生物制品公司 包含携带NF-kB抑制剂的外泌体的组合物及其使用方法
WO2022227255A1 (fr) * 2021-04-28 2022-11-03 大连干细胞与精准医学创新研究院 Procédé de préparation d'un vecteur d'administration de protéine cible

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016275046B2 (en) * 2015-06-10 2022-07-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
US10709797B2 (en) 2017-08-16 2020-07-14 City University Of Hong Kong Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy
IL277447B2 (en) * 2018-04-10 2024-04-01 Brainstorm Cell Therapeutics Ltd Cell-adapted exosomes and their uses
WO2020023594A1 (fr) * 2018-07-24 2020-01-30 Mayo Foundation For Medical Education And Research Compositions et procédés impliquant la transformation de vésicules extracellulaires
WO2020060479A1 (fr) * 2018-09-21 2020-03-26 City University Of Hong Kong Vésicules extracellulaires avec cargaison
US11766484B2 (en) * 2019-01-03 2023-09-26 International Business Machines Corporation Exosome vessels for delivery of molecular cargo
KR102125567B1 (ko) * 2019-07-02 2020-06-22 한양대학교 에리카산학협력단 식물 엑소좀의 대량 생산 방법
EP4090373A4 (fr) 2020-01-13 2024-01-17 Carmine Therapeutics Pte. Ltd. Vésicules extracellulaires de globules rouges chargées d'acide nucléique
US20230211010A1 (en) 2020-02-10 2023-07-06 Exostemtech Co., Ltd. Exosome comprising photocleavable protein, and use thereof
WO2021198961A1 (fr) * 2020-03-31 2021-10-07 Ilias Biologics Inc. Utilisation d'administration d'inhibiteurs de nf-kb à partir d'exosomes
CN114716548A (zh) 2021-01-05 2022-07-08 (株)爱恩德生物 抗-fgfr3抗体及其用途
CN116355858A (zh) * 2023-05-29 2023-06-30 北京大学 一种用于递送CRISPR-Cas9的工程化细胞外囊泡及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171290A1 (en) * 2000-08-03 2003-09-11 Carr Francis J. Peptides presented by cells
WO2013089738A1 (fr) * 2011-12-15 2013-06-20 Morehouse School Of Medicine Compositions et procédés pour l'expression ciblée d'exosomes
CN103468642A (zh) * 2013-09-23 2013-12-25 山西大学 一种分离细胞培养基中外泌体的方法
WO2016044947A1 (fr) * 2014-09-26 2016-03-31 Exerkine Corporation Exosomes utiles pour traiter une maladie de stockage lysosomal

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417229B1 (fr) * 2001-08-17 2011-06-15 Exothera L.L.C. Procedes et composes pour le ciblage de proteines vers des exosomes
KR100519384B1 (ko) 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
CN103276062A (zh) 2007-07-25 2013-09-04 路易斯维尔大学研究基金会公司 作为诊断标记物的外来体相关微rna
EP3708682B1 (fr) 2008-02-01 2022-11-23 The General Hospital Corporation Utilisation de microvésicules dans le diagnostic et le pronostic de maladies et d'état de santé
US8431530B2 (en) * 2009-06-12 2013-04-30 Morehouse School Of Medicine Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
RU2012103482A (ru) * 2009-07-02 2013-08-10 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Способ лечения рака, основанный на использовании экзосом
FR2950350B1 (fr) * 2009-09-24 2013-12-13 Centre Nat Rech Scient Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
SG183579A1 (en) * 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
WO2013048185A2 (fr) * 2011-09-30 2013-04-04 한국과학기술원 Procédé de formation d'un nano-agrégat réversible de protéines à l'aide de lumière dans une cellule
KR101433057B1 (ko) * 2012-03-07 2014-09-23 한국과학기술원 빛에 의해 ｒｔｋ 신호전달을 활성화하는 융합단백질 및 그의 용도
US11274139B2 (en) * 2013-04-12 2022-03-15 Evox Therapeutics Ltd Therapeutic delivery vesicles
WO2014172470A2 (fr) * 2013-04-16 2014-10-23 Whitehead Institute For Biomedical Research Procedes de mutation, de modification ou de modulation d'acide nucleique dans une cellule ou chez un mammifere non-humain
KR20170005854A (ko) * 2014-05-18 2017-01-16 칠드런'즈 메디컬 센터 코포레이션 엑소솜과 관련된 방법 및 조성물
US20160129098A1 (en) * 2014-11-07 2016-05-12 Wisconsin Alumni Research Foundation Targeting dna vaccines to b cells as primary antigen presenting cells
JPWO2016143805A1 (ja) * 2015-03-10 2018-02-15 テオリアサイエンス株式会社 膀胱がんの検出方法
KR20160130937A (ko) * 2015-05-04 2016-11-15 한국과학기술원 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171290A1 (en) * 2000-08-03 2003-09-11 Carr Francis J. Peptides presented by cells
WO2013089738A1 (fr) * 2011-12-15 2013-06-20 Morehouse School Of Medicine Compositions et procédés pour l'expression ciblée d'exosomes
CN103468642A (zh) * 2013-09-23 2013-12-25 山西大学 一种分离细胞培养基中外泌体的方法
WO2016044947A1 (fr) * 2014-09-26 2016-03-31 Exerkine Corporation Exosomes utiles pour traiter une maladie de stockage lysosomal

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAMBIN YIM等: "Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein–protein interaction module" *
NAMBIN YIM等: "Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein–protein interaction module", 《NATURE COMMUNICATIONS》 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110387416A (zh) * 2018-04-16 2019-10-29 华东理工大学 可控聚合调控功能的纳米金双探针体系及其应用
CN110885789A (zh) * 2018-09-05 2020-03-17 中国科学院生物物理研究所 高效可控包装內源核酸的工程化外泌体制备及其应用
CN109097336A (zh) * 2018-09-07 2018-12-28 深圳市新仑生物科技有限公司 一种干细胞外泌体、制备方法及应用
CN110669723A (zh) * 2019-11-08 2020-01-10 赵凯 一种基于差速离心法的细胞外泌体提取工艺
CN114901259A (zh) * 2019-12-30 2022-08-12 伊利亚斯生物制品公司 包含携带NF-kB抑制剂的外泌体的组合物及其使用方法
CN114901259B (zh) * 2019-12-30 2024-03-12 伊利亚斯生物制品公司 包含携带NF-kB抑制剂的外泌体的组合物及其使用方法
CN113388584A (zh) * 2020-03-10 2021-09-14 路宝特（南京）环保科技有限公司 一种促进皮肤组织损伤后修复用工程化外泌体的制备方法及其应用
CN111905105A (zh) * 2020-07-02 2020-11-10 华南师范大学 一种用于癌症靶向治疗的蛋白类纳米药物及其制备方法
WO2022227255A1 (fr) * 2021-04-28 2022-11-03 大连干细胞与精准医学创新研究院 Procédé de préparation d'un vecteur d'administration de protéine cible
CN113447658A (zh) * 2021-07-01 2021-09-28 浙江大学医学院附属儿童医院 一种检测抗过氧化物还原酶-1-IgG抗体的试剂盒

Also Published As

Publication number Publication date
AU2017335084A1 (en) 2018-05-10
EP3356522A4 (fr) 2019-03-27
EP3356522A1 (fr) 2018-08-08
AU2017335084B2 (en) 2023-06-29
JP2019528674A (ja) 2019-10-17
IL259023B (en) 2022-09-01
CA3002520A1 (fr) 2018-04-05
WO2018062973A1 (fr) 2018-04-05
IL259023A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
CN108473973A (zh) 包含负载蛋白的外泌体的组合物以及制备和递送该组合物的方法
US11872193B2 (en) Compositions containing protein loaded exosome and methods for preparing and delivering the same
US12037611B2 (en) Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
US11198712B2 (en) Secretory protein
US11760983B2 (en) Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CN106413760A (zh) 用于治疗亨廷顿病的方法和组合物
JP2013542717A5 (fr)
CN110214184A (zh) τ蛋白调节剂以及用于其递送的方法和组合物
CN109982710A (zh) 靶向增强的dna去甲基化
US11278570B2 (en) Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CN110249051A (zh) 增强功能性髓鞘产生的方法和组合物
WO2023077138A1 (fr) Compositions et systèmes pour l'édition de cellules par programmation d'arn et leurs méthodes de production et d'utilisation
CN110121555B (zh) 包含工程化内皮细胞的血脑屏障
KR101876504B1 (ko) 듀얼 리포터 유전자 동시 발현 재조합 벡터
US20230272355A1 (en) ENHANCED hAT FAMILY MEMBER SPIN TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
KR20090055868A (ko) 혈관내피세포 특이적 프로모터에 리포터 유전자가 부착된발현벡터 및 이를 이용한 혈관내피세포로의 분화 모니터링방법
WO2024137718A1 (fr) Compositions, systèmes et procédés de manipulation de neurones de l'area postrema (ap) sur la base d'une détection de gfral
KR20230041475A (ko) 뇌 종양 동물 모델의 제조 방법, 이 방법에 의해 제조된 뇌 종양 동물 모델, 및 이 모델을 이용한 뇌 종양 치료제의 스크리닝 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20191126

Address after: Han Guodatianshi

Applicant after: Elias Biological Products Co.,Ltd.

Address before: Han Guodatianshi

Applicant before: CELLEX LIFE SCIENCES Inc.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180831